Christian R Hoerner1, Rustin Massoudi2, Thomas J Metzner3, Laurel Stell4, Jennifer J O'Rourke1, Christina S Kong5, Joanna E Liliental6, James D Brooks7, Chiara Sabatti8, John T Leppert9, Alice C Fan10. 1. Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; The Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA. 2. The Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA. 3. The Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. 4. Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA. 5. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. 6. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Translational Applications Service Center (TASC) and Translational Research and Applied Medicine (TRAM) Program, Stanford University School of Medicine, Stanford, CA, USA. 7. The Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Bio-X, Stanford University, Stanford, CA, USA. 8. Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Bio-X, Stanford University, Stanford, CA, USA; Department of Statistics, Stanford University, Stanford, CA, USA. 9. The Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Bio-X, Stanford University, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA; Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: jleppert@stanford.edu. 10. Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; The Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Bio-X, Stanford University, Stanford, CA, USA. Electronic address: afan@stanford.edu.
Abstract
To personalize treatment for renal cell carcinoma (RCC), it would be ideal to confirm the activity of druggable protein pathways within individual tumors. We have developed a high-resolution nanoimmunoassay (NIA) to measure protein activity with high precision in scant specimens (eg, fine needle aspirates [FNAs]). Here, we used NIA to determine whether protein activation varied in different regions of RCC tumors. Since most RCC therapies target angiogenesis by inhibiting the vascular endothelial growth factor (VEGF) receptor, we quantified phosphorylation of extracellular signal-regulated kinase (ERK), a downstream effector of the VEGF signaling pathway. In 90 ex vivo FNA biopsies sampled from multiple regions of 38 primary clear cell RCC tumors, ERK phosphorylation differed among patients. In contrast, within individual patients, we found limited intratumoral heterogeneity of ERK phosphorylation. Our results suggest that measuring ERK in a single FNA may be representative of ERK activity in different regions of the same tumor. As diagnostic and therapeutic protein biomarkers are being sought, NIA measurements of protein signaling may increase the clinical utility of renal mass biopsy and allow for the application of precision oncology for patients with localized and advanced RCC. PATIENT SUMMARY: In this report, we applied a new approach to measure the activity of extracellular signal-regulated kinase (ERK), a key cancer signaling protein, in different areas within kidney cancers. We found that ERK activity varied between patients, but that different regions within individual kidney tumors showed similar ERK activity. This suggests that a single biopsy of renal cell carcinoma may be sufficient to measure protein signaling activity to aid in precision oncology approaches.
To personalize treatment for renal cell carcinoma (RCC), it would be ideal to confirm the activity of druggable protein pathways within individual tumors. We have developed a high-resolution nanoimmunoassay (NIA) to measure protein activity with high precision in scant specimens (eg, fine needle aspirates [FNAs]). Here, we used NIA to determine whether protein activation varied in different regions of RCC tumors. Since most RCC therapies target angiogenesis by inhibiting the vascular endothelial growth factor (VEGF) receptor, we quantified phosphorylation of extracellular signal-regulated kinase (ERK), a downstream effector of the VEGF signaling pathway. In 90 ex vivo FNA biopsies sampled from multiple regions of 38 primary clear cell RCC tumors, ERK phosphorylation differed among patients. In contrast, within individual patients, we found limited intratumoral heterogeneity of ERK phosphorylation. Our results suggest that measuring ERK in a single FNA may be representative of ERK activity in different regions of the same tumor. As diagnostic and therapeutic protein biomarkers are being sought, NIA measurements of protein signaling may increase the clinical utility of renal mass biopsy and allow for the application of precision oncology for patients with localized and advanced RCC. PATIENT SUMMARY: In this report, we applied a new approach to measure the activity of extracellular signal-regulated kinase (ERK), a key cancer signaling protein, in different areas within kidney cancers. We found that ERK activity varied between patients, but that different regions within individual kidney tumors showed similar ERK activity. This suggests that a single biopsy of renal cell carcinoma may be sufficient to measure protein signaling activity to aid in precision oncology approaches.
Authors: Roger A O'Neill; Arunashree Bhamidipati; Xiahui Bi; Debabrita Deb-Basu; Linda Cahill; Jason Ferrante; Erik Gentalen; Marc Glazer; John Gossett; Kevin Hacker; Celeste Kirby; James Knittle; Robert Loder; Catherine Mastroieni; Michael Maclaren; Thomas Mills; Uyen Nguyen; Nineveh Parker; Audie Rice; David Roach; Daniel Suich; David Voehringer; Karl Voss; Jade Yang; Tom Yang; Peter B Vander Horn Journal: Proc Natl Acad Sci U S A Date: 2006-10-19 Impact factor: 11.205
Authors: John T Leppert; Janet Hanley; Todd H Wagner; Benjamin I Chung; Sandy Srinivas; Glenn M Chertow; James D Brooks; Christopher S Saigal Journal: Urology Date: 2014-02-12 Impact factor: 2.649
Authors: L Zhou; X-D Liu; M Sun; X Zhang; P German; S Bai; Z Ding; N Tannir; C G Wood; S F Matin; J A Karam; P Tamboli; K Sircar; P Rao; E B Rankin; D A Laird; A G Hoang; C L Walker; A J Giaccia; E Jonasch Journal: Oncogene Date: 2015-09-14 Impact factor: 9.867
Authors: Dan Huang; Yan Ding; Wang-Mei Luo; Stephanie Bender; Chao-Nan Qian; Eric Kort; Zhong-Fa Zhang; Kristin VandenBeldt; Nicholas S Duesbery; James H Resau; Bin Tean Teh Journal: Cancer Res Date: 2008-01-01 Impact factor: 12.701
Authors: Alice C Fan; Debabrita Deb-Basu; Mathias W Orban; Jason R Gotlib; Yasodha Natkunam; Roger O'Neill; Rose-Ann Padua; Liwen Xu; Daryl Taketa; Amy E Shirer; Shelly Beer; Ada X Yee; David W Voehringer; Dean W Felsher Journal: Nat Med Date: 2009-04-12 Impact factor: 53.440
Authors: Marco Gerlinger; Stuart Horswell; James Larkin; Andrew J Rowan; Max P Salm; Ignacio Varela; Rosalie Fisher; Nicholas McGranahan; Nicholas Matthews; Claudio R Santos; Pierre Martinez; Benjamin Phillimore; Sharmin Begum; Adam Rabinowitz; Bradley Spencer-Dene; Sakshi Gulati; Paul A Bates; Gordon Stamp; Lisa Pickering; Martin Gore; David L Nicol; Steven Hazell; P Andrew Futreal; Aengus Stewart; Charles Swanton Journal: Nat Genet Date: 2014-02-02 Impact factor: 38.330
Authors: C Marcela Diaz-Montero; Frances J Mao; John Barnard; Yvonne Parker; Maryam Zamanian-Daryoush; John J Pink; James H Finke; Brian I Rini; Daniel J Lindner Journal: Br J Cancer Date: 2016-08-25 Impact factor: 7.640